### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Single Technology Appraisal**

# Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy ID1001

## Provisional stakeholder list of consultees and commentators

Provisional stakeholder list for the proposed technology appraisal of sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy ID1001 Issue date: January 2020

| Consultees  | Commentators (no right to submit or appeal) |
|---|---|
| Teenage Cancer Trust  | Associated Public Health Groups             |
| Tenovus Cancer Care   | Public Health England                       |
| UK Council on Deafness  | Public Health Wales                         |
| Professional groups   |   |
| Association of Cancer Physicians  |   |
| British Academy of Audiology  |   |
| <ul> <li>British Association of Audiological<br/>Physicians</li> </ul>  |   |
| <ul> <li>British Association of Educational<br/>Audiologists</li> </ul> |   |
| British Association of Otolaryngologists,<br>Head & Neck Surgeons       |   |
| British Association of Paediatricians in                                |   |
| Audiology   |   |
| British Association of Teachers of the<br>Deaf                          |   |
| British Cochlear Implant Group  |   |
| British Geriatric Society   |   |
| British Psychosocial Oncology Society                                   |   |
| British Society of Audiology  |   |
| <ul> <li>British Society of Hearing Aid<br/>Audiologists</li> </ul>     |   |
| Cancer Research UK  |   |
| Children's Cancer & Leukaemia Group                                     |   |
| Royal College of General Practitioners                                  |   |
| Royal College of Nursing  |   |
| <ul> <li>Royal College of Paediatrics &amp; Child<br/>Health</li> </ul> |   |
| Royal College of Pathologists   |   |
| Royal College of Physicians   |   |
| <ul> <li>Royal College of Speech and Language<br/>Therapists</li> </ul> |   |
| Royal Society of Medicine   |   |
| Royal Pharmaceutical Society  |   |
| UK Clinical Pharmacy Association  |   |
| UK Oncology Nursing Society   |   |
| <u>Others</u>   |   |
| Department of Health and Social Care                                    |   |
| NHS Bedfordshire CCG  |   |
| NHS East and North Hertfordshire CCG                                    |   |
| NHS England   |   |
| Welsh Government  |   |

Appendix B

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the provisional stakeholder list and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

# **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Provisional stakeholder list for the proposed technology appraisal of sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy ID1001 Issue date: January 2020

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.